Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michal Pazdernik is active.

Publication


Featured researches published by Michal Pazdernik.


Mayo Clinic Proceedings | 2010

Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota.

Daniel D. Correa de Sa; Imad M. Tleyjeh; Nandan S. Anavekar; Jason C. Schultz; Justin M. Thomas; Brian D. Lahr; Alok Bachuwar; Michal Pazdernik; James M. Steckelberg; Walter R. Wilson; Larry M. Baddour

OBJECTIVE To provide a contemporary profile of epidemiological trends of infective endocarditis (IE) in Olmsted County, Minnesota. PATIENTS AND METHODS This study consists of all definite or possible IE cases among adults in Olmsted County from January 1, 1970, through December 31, 2006. Cases were identified using resources of the Rochester Epidemiology Project. RESULTS We identified 150 cases of IE. The age- and sex-adjusted incidences of IE ranged from 5.0 to 7.9 cases per 100,000 person-years with an increasing trend over time differential with respect to sex (for interaction, P=.02); the age-adjusted incidence of IE increased significantly in women (P=.006) but not in men (P=.79). We observed an increasing temporal trend in the mean age at diagnosis (P=.04) and a decreasing trend in the proportion of cases with rheumatic heart disease as a predisposing condition (P=.02). There were no statistically significant temporal trends in the incidence of either Staphylococcus aureus or viridans group streptococcal IE. Data on infection site of acquisition were available for cases seen in 2001 and thereafter, with 50.0% designated as health care-associated, 42.5% community-acquired, and 7.5% nosocomial. CONCLUSION The incidence of IE among women increased from 1970 to 2006. Ongoing surveillance is warranted to determine whether the incidence change in women will be sustained. Subsequent analysis of infection site of acquisition and its impact on the epidemiology of IE are planned.


Biomedical Papers-olomouc | 2016

Clinical manifestations of infective endocarditis in relation to infectious agents: An 8-year retrospective study

Michal Pazdernik; Josef Kautzner; Jan Sochman; Jiri Kettner; Jan Vojáček; Radek Pelouch

AIM To compare clinical complications and outcomes of infective endocarditis (IE) episodes caused by Staphylococcus aureus (S. aureus) and other most frequent aetiological agents (streptococci, enterococci, coagulase-negative staphylococci, and culture-negative IE). METHODS A total of 117 IE episodes assessed by all internal medicine services of a major teaching institution in the Czech Republic over an eight-year period were identified. RESULTS We found that S. aureus IE episodes (n = 36) were significantly more associated with systemic embolism (41.7% vs 18.5%, P = 0.01), severe sepsis/septic shock (33.3% vs 3.7%, P < 0.0001), and in-hospital mortality (33% vs 12.3%, P = 0.01). No differences in local, structural, and/or functional complications (cardiac abscess formation, impaired integrity of the valvular apparatus, conduction disturbances, or incidence of heart failure) were observed between studied groups. Long-term survival estimates were significantly improved in patients with IE caused by agents other than S. aureus (13.78 median years vs 5.48 median years, P=0.03). CONCLUSIONS IE episodes caused by S. aureus are associated with both increased short-term and long-term mortality. Of all the studied parameters, only systemic embolism and severe sepsis/septic shock predicted in-hospital mortality.


Biomedical Papers-olomouc | 2015

Bone marrow suppression and associated consequences in patients after heart transplantation: A 6-year retrospective review

Michal Pazdernik; Ivan Malek; Eva Koudelkova; Jan Sochman; Josef Kautzner

AIMS To evaluate the incidence of bone marrow suppression and consequences of MMF dose adjustment in patients within the first year after heart transplantation. METHODS Group I (n=47) was treated with a regimen currently used in patients after heart transplantation (mycophenolatemofetil - MMF, valganciclovir - VGC and trimethoprim/sulfamethoxazole - TMP-SMX). Group II (n=47) received only MMF of potentially myelotoxic medications. The myelotoxic effect and need for dose modification were assessed. The incidence of rejections and infectious episodes associated with MMF adjustment were analyzed during the first 12 months in Group I. RESULTS There was a significantly greater proportion of patients with leukopenia (leukocyte count < 4 x 10^9/L) at 3 months after orthotopic heart transplantation in Group I compared with Group II (19.1% vs 2.1%; P = 0.02). The difference in lymphopenia (lymphocyte count < 0.8 x 10^9/L) at 3 months follow-up was highly significant (38.3 % vs 6.4 %; P = 0.0002). MMF was modified due to bone marrow suppression or severe infection in 63.8% patients in Group I and in only 8.5% of patients in Group II (P < 0.001). Reducing or stopping MMF was not associated with increased rejections. In Group I, at least 1 episode of higher degree cellular or humoral rejection occurred in 35% of patients with the standard MMF dosage compared with only 26% in patients with modified MMF (P = 0.0534). CONCLUSIONS Addition of VGC+TMP-SMX to current immunosuppressive medication regimen in patients after heart transplantation is associated with significant lymphocytopenia and leukopenia. Importantly, modification of immunosuppressive prophylaxis (reducing or stopping MMF) leads to normalization of blood count without increased incidence of rejections.


Medical Image Analysis | 2018

Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression

Zhi Chen; Michal Pazdernik; Honghai Zhang; Andreas Wahle; Zhihui Guo; Helena Bedanova; Josef Kautzner; Vojtech Melenovsky; Tomas Kovarnik; Milan Sonka

&NA; Cardiac allograft vasculopathy (CAV) accounts for about 30% of all heart‐transplant (HTx) patient deaths. For patients at high risk for CAV complications after HTx, therapy must be initiated early to be effective. Therefore, new phenotyping approaches are needed to identify such HTx patients at the earliest possible time. Coronary optical coherence tomography (OCT) images were acquired from 50 HTx patients 1 and 12 months after HTx. Quantitative analysis of coronary wall morphology used LOGISMOS segmentation strategy to simultaneously identify three wall‐layer surfaces for the entire pullback length in 3D: luminal, outer intimal, and outer medial surfaces. To quantify changes of coronary wall morphology between 1 and 12 months after HTx, the two pullbacks were mutually co‐registered. Validation of layer thickness measurements showed high accuracy of performed layer analyses with layer thickness measures correlating well with manually‐defined independent standard (RSymbol = 0.93, Symbolm), average intimal+medial thickness errors were 4.98 ± 31.24 &mgr;m, comparable with inter‐observer variability. Symbol. No caption available. Symbol. No caption available. Quantitative indices of coronary wall morphology 1 month and 12 months after HTx showed significant local as well as regional changes associated with CAV progression. Some of the newly available fully‐3D baseline indices (intimal layer brightness, medial layer brightness, medial thickness, and intimal+medial thickness) were associated with CAV‐related progression of intimal thickness showing promise of identifying patients subjected to rapid intimal thickening at 12 months after HTx from OCT‐image data obtained just 1 month after HTx. Our approach allows quantification of location‐specific alterations of coronary wall morphology over time and is sensitive even to very small changes of wall layer thicknesses that occur in patients following heart transplant.


Journal of Heart and Lung Transplantation | 2017

(395) – Highly Automated Analysis of Intimal and Medial Thickness in Heart-Transplant Coronary OCT Facilitates Longitudinal Studies of CAV Progression

Zhi Chen; Andreas Wahle; Zhihui Guo; Honghai Zhang; Vladimír Karmazín; Aleš Tomášek; Helena Bedanova; J.J. Lopez; Tomas Kovarnik; Michal Pazdernik; Milan Sonka


Journal of Heart and Lung Transplantation | 2017

Increased Heart Rate After Heart Transplant Is Not Associated with Early Progression of Cardiac Allograft Vasculopathy (CAV) - A Prospective Study Using Highly Automatic Coronary Optical Coherence Tomography Segmentation Software in 3D

Michal Pazdernik; Tomas Kovarnik; Zhi Chen; Andreas Wahle; Vladimír Karmazín; Vojtech Melenovsky; Josef Kautzner; Aleš Tomášek; Helena Bedanova; Milan Sonka


Intervenční a akutní kardiologie | 2016

Pheochromocytoma as a rare cause of ventricular fibrillation

Pavel Hajdusek; Michal Pazdernik; Jiri Kettner; Josef Kautzner


Journal of Heart and Lung Transplantation | 2018

Detecting Early Cardiac Allograft Vasculopathy Using Highly Automated 3D Coronary Optical Coherence Tomography Segmentation Analysis

Michal Pazdernik; Zhi Chen; Helena Bedanova; Josef Kautzner; Vojtech Melenovsky; Vladimír Karmazín; Ivan Malek; Aleš Tomášek; Eva Ozábalová; Jan Krejčí; Janka Franeková; Andreas Wahle; Honghai Zhang; Tomas Kovarnik; Milan Sonka


Journal of Heart and Lung Transplantation | 2018

Early detection of cardiac allograft vasculopathy using highly automated 3-dimensional optical coherence tomography analysis

Michal Pazdernik; Zhi Chen; Helena Bedanova; Josef Kautzner; Vojtech Melenovsky; Vladimír Karmazín; Ivan Malek; Aleš Tomášek; Eva Ozábalová; Jan Krejčí; Janka Franeková; Andreas Wahle; Honghai Zhang; Tomas Kovarnik; Milan Sonka


Journal of Heart and Lung Transplantation | 2017

(905) - Should We Pharmacologically Modulate Renin-Aldosterone-Angiotensin System (RAAS) to Attenuate Cardiac Allograft Vasculopathy? A Prospective Study Using Highly Automated Coronary Optical Coherence Tomography Segmentation Software in 3D

Michal Pazdernik; Tomas Kovarnik; Milan Sonka; Andreas Wahle; Zhi Chen; Vladimír Karmazín; Josef Kautzner; Aleš Tomášek; Vojtech Melenovsky; Helena Bedanova

Collaboration


Dive into the Michal Pazdernik's collaboration.

Top Co-Authors

Avatar

Josef Kautzner

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tomas Kovarnik

Charles University in Prague

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Janka Franeková

Charles University in Prague

View shared research outputs
Researchain Logo
Decentralizing Knowledge